%20(2).png)
.png)
The Ongoing Global Burden of PRRSV
PRRSV remains one of the most economically damaging infectious diseases affecting the global swine industry, contributing to billions in annual losses through respiratory disease, reproductive failure, mortality, reduced growth performance, and increased production costs.
Economic Impact
PRRSV causes major global losses through reduced productivity, treatment costs, and ongoing herd instability across commercial swine production systems.
Rapid Viral Evolution
Continuous mutation and co-circulation of Type 1 and Type 2 PRRSV strains make long-term control difficult and reduce overall vaccine effectiveness over time.
High Production Losses
Outbreaks result in respiratory disease, reproductive failure, higher piglet mortality, reduced growth rates, and increased veterinary intervention costs.
Cross-Strain Vulnerability
Monovalent vaccines often fail to protect against diverse or emerging strains, leaving herds exposed to reinfection and recurring production losses.
.png)
Introducing the CS20 Bivalent PRRSV Vaccine Platform
CS20 has been designed to address the growing complexity of PRRSV control through a dual-action vaccine strategy capable of targeting both major PRRSV genotypes simultaneously.
Bivalent Protection
Simultaneous targeting of both Type 1 and Type 2 PRRSV strains through a single vaccine platform engineered for broader immune coverage.
Reprogrammable Technology
The CS20 platform has been developed with future adaptability in mind, enabling rapid tailoring to emerging PRRSV variants and evolving regional disease pressures.
International Patent Position
The vaccine platform is supported by international intellectual property protection, strengthening its commercial and strategic licensing potential.
Commercial Relevance
Designed to support large-scale global deployment through partnership with established animal health manufacturers and commercial distributors.
Advancing Through Controlled Challenge Studies
Current development activities are focused on generating a comprehensive efficacy and safety data package through controlled live pig challenge studies designed to support future regulatory submissions and global licensing discussions.
Safety Evaluation
Assessment parameters include:
-
Reduction in viremia
-
Reduced viral shedding
-
Local tolerance assessment
-
Monitoring for adverse clinical responses
-
Evaluation of overall production performance
Efficacy Evaluation
Challenge studies are designed to demonstrate:
-
Reduced respiratory disease severity
-
Lower lung lesion scores
-
Reduced rectal temperature elevation
-
Lower viral load following heterologous challenge
-
Broader protection across genetically diverse strains
Tailored Vaccine Capability
Additional studies are evaluating the platform’s ability to be adapted toward regionally relevant and emerging PRRSV lineages, including highly pathogenic variants circulating in Asia.
Strategic Licensing & Commercial Partnership Opportunity
Black Cat Bio Limited is seeking strategic partnerships with established global animal health companies to accelerate commercialization, regulatory progression, manufacturing scale-up, and international market access for the CS20 bivalent PRRSV vaccine platform.
The company is actively exploring licensing opportunities, regulatory collaborations, manufacturing partnerships, and scientific due diligence discussions with organizations focused on advancing next-generation animal health solutions.
Qualified partners may access detailed technical and experimental data packages to support evaluation, licensing discussions, and long-term commercial collaboration.
